INBX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -3.91%, SMA50 -1.62%, SMA200 65.22%). The stock’s 14-day RSI is 46.99 (neutral), while the ATR of 5.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.33% below its high and over 614.76% above its low. Average 10-day trading volume of 295.98 thousand shares is below the 3-month average of 410.42 thousand, indicating normal recent market interest.

The latest quarter delivered EPS of -$2.15. The next quarter is forecast at -$2.08. Next year's EPS is expected at $6.22. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $150.00 to $150.00. The high target offers 68.35% upside. The low target suggests 68.35% downside. The mean target is $150.00. This offers 68.35% upside. Inhibrx Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by 28.36%. The prior quarter beat by 1.44%. Over the last six quarters, Apple has recorded several small beats. These include 9.8% in May 14, 2025.

Inhibrx Biosciences, Inc. has 14.49 million shares outstanding. The public float is 7.81 million shares, elevated short interest at 6.45% of float. This equals 676.80 thousand shares. The short ratio is 4.92 days. Institutional investors hold 115.44% of the float. Insiders own 26.95%. Eckelman Living Trust Dated February 5, 2014 holds 2.24 million shares, Eckelman Brendan P. has 1.74 million shares and Lappe Mark has 705.55 thousand shares.

Inhibrx Biosciences, Inc. last paid a dividend of 0.85 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.78. This means the shares are trading above this model’s fair value.

Inhibrx Biosciences, Inc. (NASDAQ:INBX) closed at $89.33 USD, gaining $0.23 (0.25%) from the previous close of $89.10. The stock is currently mid-range between its 52-week high and low $13.92 and $155.29. With a market capitalization of about $1.31 billion, Inhibrx Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~3.32). Key stats such as the average daily volume over the past year has been around 420.63 thousand shares, volume is running light vs its 52-week average. Headquartered in La Jolla, CA, Inhibrx Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mark Paul Lappe, the company employs approximately 156 people and listed since June 04, 2024. Inhibrx Biosciences, Inc. is a biopharmaceutical company currently in its clinical development phase, focused on creating and advancing biological treatments for patients afflicted with severe, life-threatening medical conditions.

Inhibrx Biosciences, Inc. trades at a P/E ratio of -10.72, slightly below the S&P 500 average, with a price-to-sales ratio of 1010.62 and a price-to-book ratio of -66.35 indicating negative book value, which may reflect financial stress. The P/FCF stands at -9.96, also above market averages.

Our AI price prediction model suggests that Inhibrx Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.76%, with price expected at $85.75 by June 23, 2026, within a range of $67.90 to $104.20 3-Month Outlook: Projected rise of 22.28%, reaching $108.95 by September 07, 2026, with a range of $107.07 to $110.68. 1-Year Outlook: Projected gain of 15.36%, with price at $102.79 by June 09, 2027, within a range of $94.93 to $110.61.

Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are flat -7.72% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Inhibrx Biosciences, Inc. trading at a premium to the broader market with a P/E of -10.72. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $50.45, suggesting -43.38% downside. Our AI forecast model points to short-term weakness (-3.76% over two weeks), a medium-term rise (22.28% over three months), and a longer-term gain (15.36% over one year), with expected trading ranges indicating moderate volatility.